BRPI1015131A2 - conjugados, o respectivo preparo e a respectiva aplicação em terapêutica - Google Patents

conjugados, o respectivo preparo e a respectiva aplicação em terapêutica

Info

Publication number
BRPI1015131A2
BRPI1015131A2 BRPI1015131-1A BRPI1015131A BRPI1015131A2 BR PI1015131 A2 BRPI1015131 A2 BR PI1015131A2 BR PI1015131 A BRPI1015131 A BR PI1015131A BR PI1015131 A2 BRPI1015131 A2 BR PI1015131A2
Authority
BR
Brazil
Prior art keywords
group
alkyl group
phenyl core
substituent
amino acid
Prior art date
Application number
BRPI1015131-1A
Other languages
English (en)
Inventor
Bouchard Hervé
Brun Marie-Priscille
Commerçon Alain
Zhang Jidong
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41611078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015131(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of BRPI1015131A2 publication Critical patent/BRPI1015131A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
BRPI1015131-1A 2009-06-29 2010-05-20 conjugados, o respectivo preparo e a respectiva aplicação em terapêutica BRPI1015131A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0903170A FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux
FR0903170 2009-06-29
FR0905651 2009-11-25
FR0905651A FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux
PCT/FR2010/050986 WO2011001052A1 (fr) 2009-06-29 2010-05-20 Nouveaux conjugues, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BRPI1015131A2 true BRPI1015131A2 (pt) 2018-12-04

Family

ID=41611078

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015131-1A BRPI1015131A2 (pt) 2009-06-29 2010-05-20 conjugados, o respectivo preparo e a respectiva aplicação em terapêutica

Country Status (30)

Country Link
US (1) US8952147B2 (pt)
EP (1) EP2448929A1 (pt)
JP (1) JP5746692B2 (pt)
KR (1) KR101770584B1 (pt)
CN (1) CN102482238B (pt)
AR (1) AR078131A1 (pt)
BR (1) BRPI1015131A2 (pt)
CA (1) CA2766762C (pt)
CL (1) CL2011003229A1 (pt)
CO (1) CO6430462A2 (pt)
CR (1) CR20110670A (pt)
DO (1) DOP2011000376A (pt)
EA (1) EA024627B1 (pt)
EC (1) ECSP11011553A (pt)
FR (2) FR2947269B1 (pt)
HN (1) HN2011003414A (pt)
IL (1) IL217208A (pt)
MA (1) MA33465B1 (pt)
MX (1) MX2011013764A (pt)
MY (1) MY156684A (pt)
NI (1) NI201100219A (pt)
NZ (1) NZ597136A (pt)
PE (1) PE20121031A1 (pt)
SG (2) SG10201607595WA (pt)
SV (1) SV2011004086A (pt)
TN (1) TN2011000636A1 (pt)
TW (1) TW201110986A (pt)
UY (1) UY32745A (pt)
WO (1) WO2011001052A1 (pt)
ZA (1) ZA201109537B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533992T3 (es) 2005-08-24 2015-04-16 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpo maitansinoide
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
JP5677425B2 (ja) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのピリミジノン
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA116524C2 (uk) 2011-03-29 2018-04-10 Іммуноджен, Інк. Спосіб одержання кон'югата антитіло-майтансиноїд
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2756526T3 (es) 2013-07-11 2020-04-27 Novartis Ag Modificaciones de proteínas quimioenzimáticas específicas para lisina utilizando transglutaminasa microbiana
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
TWI697493B (zh) * 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
WO2017136769A1 (en) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
MX2019013421A (es) * 2017-05-10 2020-02-05 Sanofi Sa Enlazadores peptidicos y conjugados de criptoficina, utiles en la terapia, y su preparacion.
CA3072399A1 (en) 2017-08-09 2019-02-14 Helmholtz-Zentrum Fur Infektionsforschung Gmbh New targeted cytotoxic ratjadone derivatives and conjugates thereof
AU2018389100A1 (en) * 2017-12-22 2020-07-09 Cornell University 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
EP4038085A1 (en) 2019-09-30 2022-08-10 The Regents of The University of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023057564A1 (en) 2021-10-07 2023-04-13 Sanofi IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719170A (en) 1954-07-28 1955-09-27 Du Pont Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
AU645745B2 (en) 1988-12-22 1994-01-27 Xoma Corporation Hindered linking agents and methods
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
PL185949B1 (pl) 1995-03-07 2003-09-30 Univ Hawaii Nowe związki kryptoficynowe, sposób wytwarzania nowych związków kryptoficynowych, zawierająca je kompozycja farmaceutyczna i ich zastosowanie
EP0934065B1 (en) * 1996-08-30 2006-06-07 University Of Hawaii Novel cryptophycin derivatives as anti-neoplastic agents
CA2347246A1 (en) 1998-10-16 2000-04-27 James Abraham Aikins Stereoselective process for producing cryptophycins
AU1930100A (en) 1998-12-07 2000-06-26 Eli Lilly And Company Crotylboration process to produce cryptophycin compounds
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP3851126A1 (en) 2003-05-20 2021-07-21 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
WO2005009369A2 (en) 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
AR052774A1 (es) 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
EA013323B1 (ru) * 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
WO2006096754A2 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to psma and their use as prostate cancer therapeutics
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2010014812A2 (en) 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use

Also Published As

Publication number Publication date
CA2766762C (fr) 2017-06-20
CO6430462A2 (es) 2012-04-30
IL217208A (en) 2016-02-29
ZA201109537B (en) 2013-03-27
SV2011004086A (es) 2012-05-08
SG10201607595WA (en) 2016-11-29
KR20120101981A (ko) 2012-09-17
FR2947269B1 (fr) 2013-01-18
UY32745A (es) 2011-01-31
US8952147B2 (en) 2015-02-10
PE20121031A1 (es) 2012-08-17
FR2947269A1 (fr) 2010-12-31
NZ597136A (en) 2014-04-30
JP5746692B2 (ja) 2015-07-08
TW201110986A (en) 2011-04-01
TN2011000636A1 (fr) 2013-05-24
AR078131A1 (es) 2011-10-19
MA33465B1 (fr) 2012-07-03
EP2448929A1 (fr) 2012-05-09
ECSP11011553A (es) 2012-01-31
HN2011003414A (es) 2014-11-10
CR20110670A (es) 2012-02-09
EA024627B1 (ru) 2016-10-31
JP2012531459A (ja) 2012-12-10
CN102482238B (zh) 2015-08-12
MX2011013764A (es) 2012-05-22
KR101770584B1 (ko) 2017-08-24
EA201270096A1 (ru) 2012-07-30
AU2010267917B2 (en) 2016-03-17
FR2947271B1 (fr) 2013-04-05
WO2011001052A1 (fr) 2011-01-06
US20120225089A1 (en) 2012-09-06
CN102482238A (zh) 2012-05-30
FR2947271A1 (fr) 2010-12-31
DOP2011000376A (es) 2012-01-15
MY156684A (en) 2016-03-15
CA2766762A1 (fr) 2011-01-06
IL217208A0 (en) 2012-03-01
SG177419A1 (en) 2012-02-28
CL2011003229A1 (es) 2012-06-29
NI201100219A (es) 2012-05-23
AU2010267917A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
BRPI1015131A2 (pt) conjugados, o respectivo preparo e a respectiva aplicação em terapêutica
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
NZ621981A (en) Lipid compositions
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
RS51590B (en) IMIDASO [1,2-A] Pyridine Compounds as VEGF-R2 Inhibitors
EA201591000A1 (ru) Пирролобензодиазепины
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
NO20041891L (no) Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer
IN2014DN03483A (pt)
EA201171328A1 (ru) Производное замещенного изохинолина
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
MX2015005637A (es) Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
CO6362007A2 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
CY1111601T1 (el) Παραγωγα καρβοξαμιδιων της τριαζολοπυριδινης, η παρασκευη τους και η θεραπευτικη χρηση τους
MA32884B1 (fr) Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique
BR112012007991B8 (pt) uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas
ATE525367T1 (de) Neue pyrocatechinderivate
UA88766C2 (ru) Производные хинолина для лечения латентного туберкулеза
EA201070819A1 (ru) Соединения n-фенилимидазо[1,2-a]пиридин-2-карбоксамида, их получение и их применени в терапии
UA108473C2 (uk) Кон'югати, їхнє одержання і застосування в терапії
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2011134444A3 (en) Substitution derivatives of n6-benzyladenosine-5´-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL